MetaVia is trading at $1.22, down 8.96% during the November 5 session; no clear company-specific negative catalyst was identified.

  • MetaVia announced positive interim Phase 1 results for DA-1726.
  • After 16 weeks, results included a 68% placebo-adjusted liver-fat reduction and a 13.5% placebo-adjusted weight reduction.
  • The Nasdaq was down 1.94%, consistent with broader market pressure, though this does not establish the cause of MetaVia’s decline.